Retarpen 1,2 (Benzathine Benzylpenicillin) is used to address specific bacterial threats and help manage susceptible pathogens. Its application may assist in providing supportive long-term relief.

The medication is commonly used to help manage conditions presenting with systemic or localized discomfort, including treponemal infections like Syphilis and the acute management of streptococcal pharyngitis. Its sustained characteristics may assist in long-term prevention (prophylaxis) against the recurrence of conditions associated with acute or episodic changes like Acute Rheumatic Fever in patients, particularly children and adolescents. The treatment supports the healing of characteristic lesions and is applied in addressing the source of infection.

“This sustained coverage helps improve day-to-day comfort during symptomatic periods and may assist in reducing the risk of subsequent bacterial triggers.”

Quick Fact: Relief for Prophylaxis
Primary Benefit	Provides supportive relief and may assist in managing the risk of recurrent post-infection complications.
Symptom Category	Addressing pathogen presence that creates a risk of systemic imbalance.
Use Scenario	Commonly used in pediatric and high-risk patients requiring continuous supportive protection.

The eligibility profile for Retarpen 1,2 (Benzathine Benzylpenicillin) is defined by absolute prohibitions and conditional use restrictions documented in official regulatory labeling.

Who Must Not Use Retarpen 1,2 (Contraindications)

The medicine is strictly contraindicated if a patient has a documented history of hypersensitivity to any Penicillin or a severe immediate reaction to any other Beta-lactam agent (e.g., cephalosporins). It is also contraindicated for patients with a known allergy to soya or peanut due to potential excipient components. Furthermore, the medicine is strictly prohibited for intravenous (IV) or intra-arterial (IA) administration; its use is restricted only to deep intramuscular injection.

Populations Requiring Conditional Use

Use is established across all age groups, from neonates to older adults. However, special caution and possible dose adjustment are required for patients with renal impairment. Caution is also necessary for patients with impaired hepatic function and those with pre-existing conditions like bronchial asthma. Use during pregnancy is permitted when clearly indicated, but use during lactation is restricted and requires careful consideration of the potential effects on the infant. The medicine is not the appropriate formulation for treating Neurosyphilis.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Retarpen 1,2 (Benzathine Benzylpenicillin) as listed in regulatory prescribing information.

Interactions Affecting Drug Exposure and Clearance

• Probenecid: Co-administration with Probenecid prolongs the antibiotic's presence in the bloodstream. This pharmacokinetic interaction occurs because Probenecid competitively inhibits the renal tubular secretion of penicillin, thereby reducing its clearance and maintaining elevated serum levels.
• Methotrexate: Benzathine Benzylpenicillin reduces the excretion of Methotrexate. This mechanism is officially documented as potentially increasing Methotrexate toxicity, and for this reason, the combination is generally not recommended by regulatory agencies.

Pharmacodynamic and Systemic Risk

• Tetracyclines: Concurrent use with bacteriostatic antibiotics, such as Tetracyclines, should be avoided. This is due to the potential for the bacteriostatic medicine to formally antagonize the bactericidal effect of penicillin.
• Oral Anticoagulants: The co-administration of this antibiotic with oral anticoagulants may intensify the anti-vitamin K effect, which increases the documented risk of bleeding.

Specific Regulatory Constraints

• Lidocaine Solution: If a Lidocaine solution is used to reconstitute the powder for injection, the official documentation requires that all existing contraindications for Lidocaine must be formally excluded before administration.
• Impaired Renal Function: Patients with impaired renal function carry a greater risk of toxic reactions because the drug is substantially excreted by the kidney. This condition may amplify the effects of exposure-modifying interactions.

The mechanism of Retarpen 1,2 is a highly targeted, bactericidal process that involves both molecular action and a specialized delivery system to ensure prolonged duration of effect.

Molecular Inhibition of Bacterial Cell Wall Construction

Retarpen 1,2’s active component, Benzylpenicillin (Penicillin G), exerts its effect by targeting specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are crucial transpeptidases. The drug irreversibly binds to and inactivates these enzymes . This covalent inhibition blocks the cross-linking of the bacterial cell wall’s peptidoglycan layer, which immediately renders the cell wall structurally deficient.

---

Causal Cascade Leading to Osmotic Lysis

By blocking cell wall synthesis during the bacterial growth phase, the mechanism initiates a catastrophic molecular cascade. The unstable, incomplete cell wall is unable to withstand the high internal fluid pressure, which leads to the subsequent physical breakdown and bursting, or osmotic lysis, of the bacterial cell. This process, often accelerated by bacterial autolytic enzymes that are disinhibited by the drug, results in cell lysis and irreversible bacterial death.

---

Mechanism Sustained by Depot Release

The mechanism's functional duration is extended by the Benzathine salt, which forms a non-active depot at the injection site. The slow, gradual hydrolysis of this low-solubility salt releases the active Benzylpenicillin molecule into the circulation over an extended period. This system maintains a concentration above the Minimum Inhibitory Concentration ( C min), supporting the sustained engagement of the molecular target.

How Retarpen 1,2 is Used: Administration Guidelines

Retarpen 1,2 (Benzathine Benzylpenicillin) is a long-acting depot preparation that requires standard administration procedures. The instructions detail the required administration route, dose schedule, and preparation methods.

---

Administration and Preparation

The route for this medicine is Deep Intramuscular (IM) Injection Only, and Intravenous (IV) or Intra-arterial administration is strictly prohibited.

The medication is prepared from a powder and solvent that must be reconstituted into a suspension and shaken vigorously. The injection is given at a slow, steady rate into the upper, outer quadrant of the buttock in adults, or the mid-lateral thigh in small children. Aspiration must be performed before injection to ensure the needle is not in a blood vessel. For large volumes (e.g., 2.4 Million IU), the dose may be divided and administered into two separate injection sites.

---

Dosing Schedules

Dosage and duration vary based on the specific condition, following patterns of either single curative doses or long-term prophylaxis:

Patient Group	Standard Dosing Regimen (Examples)	Frequency / Duration
Adults (Acute Infection)	1.2 Million IU	Single dose
Adults (Late Latent Syphilis)	2.4 Million IU	Once weekly for 3 weeks (total 7.2 Million IU)
Pediatric (Prophylaxis ge 30 kg)	1.2 Million IU	Every 3 to 4 weeks

Population-Specific Use

Dosage adjustments are required for specific populations. For instance, pediatric dosing for acute infections is determined by weight (e.g., children under 30 kg may receive 600,000 IU), and patients with renal impairment require a dose reduction based on creatinine clearance levels to support appropriate use.

Recent Clinical Evidence Overview

Retarpen 1,2 (Benzathine Benzylpenicillin) is a long-acting formulation of penicillin G. Recent clinical research primarily focuses on optimizing treatment regimens for established uses, particularly early syphilis, and confirming bioequivalence for various formulations.

---

Research on Syphilis Treatment Regimens

A large, multi-site, randomized, controlled clinical trial funded by the NIH evaluated the effectiveness of a single injection regimen versus the standard three-weekly injection regimen for treating early syphilis (primary, secondary, and early latent stages). This research included both individuals with and without HIV infection.

Regimen Evaluated	Serological Response at 6 Months (Combined)
Single 2.4 MU Dose	76%
Three Weekly 2.4 MU Doses	70%

Trial results indicated that the single-dose regimen was noninferior to the three-dose regimen in achieving the primary endpoint (serological response at six months). These findings suggest a potential for simplifying treatment protocols, which may improve patient adherence and support antimicrobial stewardship efforts. The study noted that the serological response did not differ significantly when participants were stratified by HIV status.

---

Pharmacokinetic and Bioequivalence Studies

Pharmacokinetic studies continue to examine the sustained-release properties of benzathine penicillin G. Research has confirmed that the concentration of the drug remains detectable in the bloodstream for up to 14 days or longer following a single 1.2 million unit injection in adults. Additionally, bioequivalence testing has demonstrated that generic and innovator formulations of benzathine penicillin G 1.2 million units are statistically equivalent based on the rate and extent of absorption in healthy individuals.

Common questions about Retarpen 1,2 (FAQ)

Q: What specific bacterial infections is Retarpen 1,2 licensed to treat?

Official prescribing information indicates that this medicine is approved for treating specific infections caused by susceptible bacteria. These include treponemal infections like syphilis, yaws, bejel, and certain upper respiratory tract infections, such as strep throat. It is also officially used for the long-term prevention (prophylaxis) of conditions like rheumatic fever.

Q: Is it common to have pain or a lump at the Retarpen 1,2 injection site?

Yes, official regulatory documents state that reactions at the injection site are a documented side effect of this medicine. These reactions can include pain, inflammation, and the formation of a lump (infiltrate). The long-acting nature of the injection is associated with discomfort at the site.

Q: Is diarrhea a possible side effect of Retarpen 1,2, even after the treatment is over?

Diarrhea is listed as a common side effect of this type of antibiotic treatment. Official warnings state that gastrointestinal issues, including severe diarrhea (pseudomembranous colitis), can occur not only during treatment but also several weeks after the medicine has been administered.

Q: What is the connection between Retarpen 1,2 and Group A Streptococcus (strep throat)?

The official product information specifies that this medicine is used to treat infections caused by susceptible Group A Streptococcal bacteria, which are responsible for illnesses like pharyngitis (strep throat). The medicine is also indicated for the long-term prevention of rheumatic fever, which is a possible complication following an untreated strep infection.

Q: Can Retarpen 1,2 interact with common over-the-counter pain relievers?

While official labels do not specifically name all over-the-counter pain relievers, they do list other medicines that share a common kidney clearance pathway. This means taking certain pain relievers concurrently may slow the removal of Retarpen 1,2 from the body, which could increase its concentration in the bloodstream.

Q: Are there any known interactions between Retarpen 1,2 and oral contraceptives?

Official medical guidance advises that penicillins, including this formulation, may reduce the effectiveness of oral contraceptives in some women. This potential interaction could increase the risk of an unintended pregnancy or cause breakthrough bleeding.

Q: What is the Jarisch-Herxheimer reaction, and is it a concern with Retarpen 1,2?

The Jarisch-Herxheimer reaction is a specific event documented in official warnings when this medicine is used for the treatment of syphilis. It involves a temporary, systemic reaction that may include symptoms such as fever, chills, headache, and joint pain. This reaction typically occurs shortly after the initial dose.

Q: Does Retarpen 1,2 interact with alcohol consumption?

Official regulatory documents do not list a specific, critical chemical interaction between this medicine and alcohol. As with any medication for infection, general guidance often involves limiting alcohol use.

Q: What are the risks if I stop my Retarpen 1,2 treatment earlier than prescribed?

Official patient information notes that the full prescribed treatment schedule is important. Stopping the treatment too soon or missing doses may result in an incomplete clearance of the infection and can contribute to the bacteria developing drug resistance, potentially making future infections harder to treat.

Q: Can Retarpen 1,2 be used for conditions like the common cold or flu?

This medicine is classified as an antibiotic and is designed to eliminate specific bacteria. Official warnings state that it is ineffective against viruses, which are the cause of common conditions like the cold and flu. Using an antibiotic when it is not needed can increase the risk of the body developing antibiotic resistance.

Q: What is the procedure for a missed appointment or a late injection of Retarpen 1,2?

Regulatory patient information notes that a fixed treatment schedule is necessary to maintain effectiveness. If a scheduled injection is missed, the official guidance is to consult with the prescribing healthcare professional to determine the appropriate next steps.

Q: Can Retarpen 1,2 interact with herbal supplements or vitamins?

The official label contains a general warning regarding potential interactions and references the need for the prescribing professional to be informed about all other medications, including vitamins, nutritional supplements, and herbal products, as this medicine may affect how other products work in the body.

Q: Does Retarpen 1,2 cause a metallic or unusual taste in the mouth?

Abnormal taste perception, known medically as dysgeusia, has been reported in association with the active ingredient (penicillin G). This is listed as a potential side effect in official adverse reaction reports.

Q: Can Retarpen 1,2 be associated with joint or muscle aches?

Official adverse event reports list both joint pain and muscle cramps or pain as potential side effects. These reports document that such events have occurred in patients using this medicine, although the frequency is not always specified.

Q: Is a severe headache a potential side effect of Retarpen 1,2?

Headache is listed in official documents as a reported side effect of this medicine. Furthermore, headache is a documented part of the Jarisch-Herxheimer reaction, which is a systemic response associated with this drug's use in certain infections.

Q: Why is a period of observation sometimes required after receiving Retarpen 1,2?

A period of observation is sometimes part of the administration procedure because regulatory information documents that a severe allergic reaction (anaphylaxis) is a potentially life-threatening risk associated with the drug. Being observed allows immediate medical treatment if a reaction were to occur.

Q: What are the general expectations for patient monitoring during Retarpen 1,2 treatment?

Official product information includes the expectation that patients will attend follow-up appointments prescribed by their doctor. The documents also describe that the prescribing professional should be consulted immediately if certain severe side effects, such as persistent or severe diarrhea, occur.

Q: What is the official classification regarding the risk of birth defects with Retarpen 1,2?

Official regulatory information indicates that the risk of the medicine causing a birth defect (malformative risk) is considered unlikely. The medicine is generally classified as acceptable for use during pregnancy when a clear clinical need is established, as animal studies showed no evidence of fetal harm.

Q: What is the risk of antibiotic resistance related to Retarpen 1,2?

Official warnings caution that prescribing any antibiotic, including this one, in the absence of a confirmed bacterial infection or a documented need for prevention increases the risk of drug-resistant bacteria developing. This emphasizes the importance of appropriate use.

How to Store and Dispose of Retarpen 1,2 Million I.U.

The storage of Retarpen 1,2 (Benzathine Benzylpenicillin) is determined by the preparation state, according to official regulatory documentation.

Storage Requirements

Product State	Storage Instruction	Stability Constraint
Unreconstituted Powder	No special storage conditions are required. Keep the vial in the original container (carton).	Stable for its labeled shelf-life.
Reconstituted Suspension	Must be used immediately after mixing.	No post-reconstitution storage is permitted.

All medicines must be kept out of the sight and reach of children.

Disposal

Any unused or expired medicinal product, including waste material, must be disposed of in accordance with local requirements. Patients are instructed to return unused medicine to a pharmacist to ensure proper pharmaceutical waste handling and prevent disposal in household waste or wastewater.